Jaypirca is approved for the treatment of adults with relapsed or refractory CLL/SLL who were previously treated with a ...

Several ransomware groups have been spotted using a packer-as-a-service (PaaS) platform named Shanya to assist in EDR ...

In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met ...

Indianapolis: Eli Lilly and Company has announced results from the Phase 3 BRUIN CLL-314 clinical trial evaluating Jaypirca ...

Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...

Based on the Results of a Planned Interim Futility Analysis the Inhaled AAT Trial is Unlikely to Demonstrate a Statistically ...

Choosing an ITSM platform can feel a bit like choosing a long-term partner: you’re not just buying features, you’re ...

Lilly reports Phase 3 CLL results showing Jaypirca matched and improved on Imbruvica across response rates and early progression trends, with safety consistent between treatments.

In addition to meeting the primary endpoint of non-inferiority for overall response rate (ORR) in the BRUIN CLL-314 study, pirtobrutinib achieved a numerically higher ORR of 87.0% compared to 78.5% ...

Kamada ends its Phase 3 inhaled AAT trial after a futility analysis but maintains 2025 guidance and forecasts double-digit growth in 2026.

According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a ...

Shares of Praxis Precision Medicines PRAX have skyrocketed 519.5% in the past three months. The sharp rally in the stock was ...